Stock Scorecard
Stock Summary for Intellia Therapeutics Inc (NTLA) - $24.00 as of 10/15/2025 7:49:56 AM EST
Total Score
7 out of 30
Safety Score
41 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for NTLA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for NTLA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for NTLA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for NTLA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for NTLA (41 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for NTLA
Financial Details for NTLA
Company Overview |
|
|---|---|
| Ticker | NTLA |
| Company Name | Intellia Therapeutics Inc |
| Country | USA |
| Description | Intellia Therapeutics, Inc. (NTLA) is a pioneering genome editing company based in Cambridge, Massachusetts, dedicated to developing transformative therapies for genetic diseases through its proprietary CRISPR/Cas9 technology. The company is at the forefront of utilizing its innovative platform to create targeted treatments that address a wide range of conditions, with ongoing clinical trials illustrating its commitment to advancing precision medicine. As a leader in the rapidly evolving field of gene editing, Intellia's strategic partnerships and intellectual property portfolio position it well for substantial growth and impact in the biotechnology landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/6/2025 |
Stock Price History |
|
| Last Day Price | 24.00 |
| Price 4 Years Ago | 118.24 |
| Last Day Price Updated | 10/15/2025 7:49:56 AM EST |
| Last Day Volume | 4,928,531 |
| Average Daily Volume | 6,867,859 |
| 52-Week High | 26.98 |
| 52-Week Low | 5.90 |
| Last Price to 52 Week Low | 306.78% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.31 |
| Sector PE | 40.41 |
| 5-Year Average PE | -10.65 |
| Free Cash Flow Ratio | 16.55 |
| Industry Free Cash Flow Ratio | 14.26 |
| Sector Free Cash Flow Ratio | 29.23 |
| Current Ratio Most Recent Quarter | 5.19 |
| Total Cash Per Share | 1.45 |
| Book Value Per Share Most Recent Quarter | 6.79 |
| Price to Book Ratio | 3.07 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.01 |
| Price to Sales Ratio Twelve Trailing Months | 49.80 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.64 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.78 |
| Analyst Buy Ratings | 16 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 107,347,000 |
| Market Capitalization | 2,576,328,000 |
| Institutional Ownership | 88.02% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -7.86% |
| Reported EPS 12 Trailing Months | -4.69 |
| Reported EPS Past Year | -2.08 |
| Reported EPS Prior Year | -5.25 |
| Net Income Twelve Trailing Months | -480,194,000 |
| Net Income Past Year | -519,021,000 |
| Net Income Prior Year | -481,192,000 |
| Quarterly Revenue Growth YOY | 104.80% |
| 5-Year Revenue Growth | 6.07% |
| Operating Margin Twelve Trailing Months | -772.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 156,172,000 |
| Total Cash Past Year | 189,182,000 |
| Total Cash Prior Year | 226,748,000 |
| Net Cash Position Most Recent Quarter | 156,172,000 |
| Net Cash Position Past Year | 189,182,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 871,956,000 |
| Total Stockholder Equity Prior Year | 1,050,169,000 |
| Total Stockholder Equity Most Recent Quarter | 715,255,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -421,818,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.93 |
| Free Cash Flow Past Year | -354,658,000 |
| Free Cash Flow Prior Year | -408,071,000 |
Options |
|
| Put/Call Ratio | 0.16 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 3.02 |
| MACD Signal | 2.32 |
| 20-Day Bollinger Lower Band | 3.94 |
| 20-Day Bollinger Middle Band | 13.09 |
| 20-Day Bollinger Upper Band | 22.24 |
| Beta | 2.38 |
| RSI | 79.77 |
| 50-Day SMA | 11.46 |
| 150-Day SMA | 24.71 |
| 200-Day SMA | 35.09 |
System |
|
| Modified | 10/14/2025 5:35:07 AM EST |